Samsung Pharm Total Assets
Samsung Pharm total assets. Based on the latest financial reports, Samsung Pharm (001360) holds total assets worth ₩224.14 Billion KRW (≈ $151.89 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Samsung Pharm stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Samsung Pharm (2012–2024)
Total assets of Samsung Pharm from 2012 to 2024. This chart illustrates how Samsung Pharm's total assets have evolved over time, based on quarterly financial data. See current stock price of Samsung Pharm for real-time trading data and today's change.
Samsung Pharm - Asset Composition Analysis
Samsung Pharm Total Assets Breakdown (December 2024)
Samsung Pharm total assets breakdown as of December 2024. Samsung Pharm's total assets of ₩224.14 Billion consist of 36.6% current assets and 63.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.8% |
| Accounts Receivable | ₩4.76 Billion | 3.7% |
| Inventory | ₩20.07 Billion | 15.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.61 Billion | 4.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Samsung Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 001360 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Samsung Pharm's current assets represent 36.6% of total assets in 2024, a decrease from 66.8% in 2012.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2024, down from 8.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 15.6% of total assets.
Samsung Pharm Competitors by Total Assets
Key competitors of Samsung Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Samsung Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 3.08 | 1.30 |
| Quick Ratio | 1.23 | 2.09 | 1.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩21.75 Billion | ₩38.07 Billion | ₩15.12 Billion |
Samsung Pharm - Advanced Valuation Insights
This section examines the relationship between Samsung Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.11 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 37.4% |
| Total Assets | ₩128.45 Billion |
| Market Capitalization | $76.73 Million USD |
Valuation Analysis
Below Book Valuation: The market values Samsung Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Samsung Pharm's assets grew by 37.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Samsung Pharm (2012–2024)
The table below shows the annual total assets of Samsung Pharm from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩128.45 Billion ≈ $87.05 Million |
+37.41% |
| 2023-12-31 | ₩93.48 Billion ≈ $63.35 Million |
-20.72% |
| 2022-12-31 | ₩117.91 Billion ≈ $79.91 Million |
-18.93% |
| 2021-12-31 | ₩145.46 Billion ≈ $98.57 Million |
-18.62% |
| 2020-12-31 | ₩178.73 Billion ≈ $121.12 Million |
+6.05% |
| 2019-12-31 | ₩168.53 Billion ≈ $114.21 Million |
+4.91% |
| 2018-12-31 | ₩160.65 Billion ≈ $108.87 Million |
+4.18% |
| 2017-12-31 | ₩154.19 Billion ≈ $104.50 Million |
+11.50% |
| 2016-12-31 | ₩138.28 Billion ≈ $93.71 Million |
+6.20% |
| 2015-12-31 | ₩130.22 Billion ≈ $88.25 Million |
+126.82% |
| 2014-12-31 | ₩57.41 Billion ≈ $38.91 Million |
-44.27% |
| 2012-12-31 | ₩103.02 Billion ≈ $69.81 Million |
-- |
About Samsung Pharm
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamin… Read more